AI
| Followers | 843 |
| Posts | 122802 |
| Boards Moderated | 10 |
| Alias Born | 09/05/2002 |
Sunday, January 27, 2008 7:29:43 PM
Re: FLML
>somewhere below locteron (since we haven't seen the full VL data yet), but above "the other interferons", since there is positive top line data in a comparator clinical trial vs pegylated interferon<
In reviewing FLML’s PR from October, it seems that all we have is the company’s assurance that the top-line data were positive (#msg-24008801). Therefore, I think I’ll put IFN-alpha-XL in the same group with Albuferon and IFN-Lambda. Feel free to argue for a different placement
>somewhere below locteron (since we haven't seen the full VL data yet), but above "the other interferons", since there is positive top line data in a comparator clinical trial vs pegylated interferon<
In reviewing FLML’s PR from October, it seems that all we have is the company’s assurance that the top-line data were positive (#msg-24008801). Therefore, I think I’ll put IFN-alpha-XL in the same group with Albuferon and IFN-Lambda. Feel free to argue for a different placement
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Trade Smarter with Thousands
Leverage decades of market experience shared openly.
